MedTrace Logo

Intervention of Nicotinamide Mononucleotide in Middle-aged and Elderly People

NCT06592859 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2026-05-08

No results posted yet for this study

Summary

This study is a single-center, randomized, double-blind, placebo-controlled clinical trial investigating a pharmacological intervention for aging. Its primary objective is to evaluate the efficacy of NMN while ensuring the safety of oral administration, with the aim of identifying effective strategies to delay aging and improve the quality of life in the elderly population. The main outcomes of this study are to characterize the patterns of NMN efficacy across different populations and to identify sensitive biomarkers that reflect responsiveness to the intervention.

Conditions

  • Aging
  • NMN

Interventions

DIETARY_SUPPLEMENT

NMN

NMN Arm participants took one capsule (containing 350mg NMN or placebo) with breakfast daily for one year.

DIETARY_SUPPLEMENT

placebo

Placebo arm participants took one capsule (appearance and odor are the same as NMN) with breakfast daily for one year.

Sponsors & Collaborators

  • Beijing Institute of Genomics, Chinese Academy of Sciences

    collaborator OTHER_GOV

  • Institute of Zoology, Chinese Academy of Sciences

    collaborator OTHER_GOV

  • People's Hospital of Quzhou

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
39 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-08-23
Primary Completion
2026-05-24
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06592859 on ClinicalTrials.gov